Spectrum Pharmaceuticals Appoints New President and COO - - BioPharm International


Spectrum Pharmaceuticals Appoints New President and COO

Spectrum Pharmaceuticals, a biotechnology company with a primary focus in hematology and oncology, has appointed Joseph Turgeon, previously senior vice president and COO, as president and COO, replacing Ken Keller. Thomas Riga, previously vice president, corporate accounts, will become the senior vice president, COO.

Turgeon joined Spectrum in October 2012 and has over 30 years of pharmaceutical sales experience. Prior to joining the Spectrum, hespent 22 years at Amgen as VP of sales. Riga has over 15 years of pharmaceutical sales and management experience and has worked at Amgen, EliLilly, and Dendreon.

Source: Spectrum Pharmaceuticals

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here